NUR2474 Pharmacology for Professional
Nursing Actual Exam 2026/2027 with
Detailed Rationales | Complete Exam-Style
Questions | Pass Guaranteed – A+ Graded
Section 1: Pharmacokinetics & Pharmacodynamics (Questions
1–7)
Q1: A 68-year-old patient with chronic kidney disease (CrCl 28 mL/min) is prescribed gentamicin 80
mg IV q8h. The nurse reviews the pharmacokinetic profile and recognizes that which parameter is
most significantly altered in this patient?
A. Absorption from the GI tract is decreased due to uremic gastritis
B. Distribution is increased due to higher plasma protein binding
C. Elimination is prolonged due to reduced renal clearance [CORRECT]
D. Metabolism is enhanced due to compensatory hepatic function
Correct Answer: C
Rationale:
, ● (a) Pharmacological principle: Gentamicin is an aminoglycoside antibiotic that is primarily
eliminated unchanged by glomerular filtration. The kidneys excrete approximately 90% of the
drug within 24 hours. Chronic kidney disease with CrCl <30 mL/min significantly reduces
elimination, leading to prolonged half-life and increased risk of nephrotoxicity and ototoxicity.
● (b) Clinical reasoning pathway: Assessment (CrCl 28 mL/min indicates Stage 4 CKD) →
Intervention (dose reduction or extended interval required per pharmacy protocol) →
Evaluation (monitor peak/trough levels and renal function).
● (c) Distractor analysis: A is incorrect because gentamicin is given IV, bypassing GI absorption.
B is incorrect because gentamicin has minimal protein binding (0-10%), and uremia actually
reduces protein binding of some drugs. D is incorrect because hepatic metabolism does not
compensate for renal elimination of renally-cleared drugs.
● (d) Reference: Rasmussen NUR2474 Module 1 (Pharmacokinetics); NCLEX Pharmacological
Therapies: Expected Actions/Outcomes.
Q2: A patient receiving IV morphine 4 mg q4h PRN for postoperative pain reports increased sedation
and respiratory rate of 10 breaths/min. The nurse understands that these findings represent which
pharmacodynamic concept?
A. Drug tolerance requiring increased dosing
B. Anaphylactic reaction to the opioid
C. Agonist effect at mu-opioid receptors exceeding therapeutic threshold [CORRECT]
D. Antagonist effect causing withdrawal symptoms
Correct Answer: C
Rationale:
● (a) Pharmacological principle: Morphine is a pure mu-opioid receptor agonist. At therapeutic
doses, it produces analgesia; however, excessive agonist activity causes dose-dependent
, adverse effects including respiratory depression (mediated by mu-2 receptors in the
brainstem respiratory centers) and sedation.
● (b) Clinical reasoning pathway: Assessment (RR 10, increased sedation = respiratory
depression) → Intervention (hold next dose, prepare naloxone, notify provider, monitor
oxygenation) → Evaluation (improved respiratory status after intervention).
● (c) Distractor analysis: A is incorrect because tolerance would require higher doses for effect,
not toxicity at current dose. B is incorrect because anaphylaxis presents with hypotension,
bronchospasm, and urticaria, not respiratory depression. D is incorrect because antagonists
block receptors and would cause withdrawal, not sedation.
● (d) Reference: Rasmussen NUR2474 Module 2 (Pharmacodynamics); NCLEX Reduction of
Risk Potential: System Specific Assessments.
Q3: A nurse is teaching a patient about warfarin therapy. Which statement by the patient
demonstrates understanding of the drug's mechanism of action?
A. "It dissolves blood clots that have already formed in my veins."
B. "It prevents my liver from making clotting factors that depend on vitamin K." [CORRECT]
C. "It makes my platelets less sticky so they don't clump together."
D. "It increases the breakdown of fibrin in my bloodstream."
Correct Answer: B
Rationale:
● (a) Pharmacological principle: Warfarin is a vitamin K antagonist that inhibits vitamin K
epoxide reductase (VKORC1), preventing the gamma-carboxylation of clotting factors II, VII,
IX, and X in the liver. This creates functionally inactive clotting factors, reducing coagulation
capacity.
● (b) Clinical reasoning pathway: Patient teaching (mechanism explanation) → Patient
response (accurate restatement) → Evaluation (understanding confirmed, adherence
promoted).
, ● (c) Distractor analysis: A describes thrombolytics (alteplase). C describes antiplatelet agents
(aspirin, clopidogrel). D describes fibrinolytic activity (not warfarin's mechanism).
● (d) Reference: Rasmussen NUR2474 Module 4 (Anticoagulants); NCLEX Pharmacological
Therapies: Medication Administration.
Q4: A patient with a history of liver cirrhosis is prescribed lorazepam 2 mg PO at bedtime for anxiety.
The nurse should anticipate which pharmacokinetic alteration?
A. Increased first-pass metabolism leading to lower bioavailability
B. Decreased metabolism leading to drug accumulation and prolonged effect [CORRECT]
C. Increased renal excretion of the active metabolite
D. Enhanced absorption due to portal hypertension
Correct Answer: B
Rationale:
● (a) Pharmacological principle: Lorazepam undergoes hepatic metabolism via glucuronidation
(Phase II). Cirrhosis reduces functional hepatocytes and hepatic blood flow, impairing drug
metabolism. This leads to prolonged elimination half-life, increased drug accumulation with
repeated dosing, and enhanced CNS depression.
● (b) Clinical reasoning pathway: Assessment (liver dysfunction + benzodiazepine order) →
Intervention (dose reduction, extended interval, or alternative drug; monitor for oversedation)
→ Evaluation (therapeutic effect without excessive sedation).
● (c) Distractor analysis: A is incorrect because first-pass metabolism is decreased, not
increased, in liver disease. C is incorrect because lorazepam's metabolites are inactive and
renal excretion is not clinically significant. D is incorrect because portal hypertension does not
enhance drug absorption.
● (d) Reference: Rasmussen NUR2474 Module 1 (Hepatic metabolism); NCLEX
Pharmacological Therapies: Adverse Effects/Contraindications/Side Effects.
Nursing Actual Exam 2026/2027 with
Detailed Rationales | Complete Exam-Style
Questions | Pass Guaranteed – A+ Graded
Section 1: Pharmacokinetics & Pharmacodynamics (Questions
1–7)
Q1: A 68-year-old patient with chronic kidney disease (CrCl 28 mL/min) is prescribed gentamicin 80
mg IV q8h. The nurse reviews the pharmacokinetic profile and recognizes that which parameter is
most significantly altered in this patient?
A. Absorption from the GI tract is decreased due to uremic gastritis
B. Distribution is increased due to higher plasma protein binding
C. Elimination is prolonged due to reduced renal clearance [CORRECT]
D. Metabolism is enhanced due to compensatory hepatic function
Correct Answer: C
Rationale:
, ● (a) Pharmacological principle: Gentamicin is an aminoglycoside antibiotic that is primarily
eliminated unchanged by glomerular filtration. The kidneys excrete approximately 90% of the
drug within 24 hours. Chronic kidney disease with CrCl <30 mL/min significantly reduces
elimination, leading to prolonged half-life and increased risk of nephrotoxicity and ototoxicity.
● (b) Clinical reasoning pathway: Assessment (CrCl 28 mL/min indicates Stage 4 CKD) →
Intervention (dose reduction or extended interval required per pharmacy protocol) →
Evaluation (monitor peak/trough levels and renal function).
● (c) Distractor analysis: A is incorrect because gentamicin is given IV, bypassing GI absorption.
B is incorrect because gentamicin has minimal protein binding (0-10%), and uremia actually
reduces protein binding of some drugs. D is incorrect because hepatic metabolism does not
compensate for renal elimination of renally-cleared drugs.
● (d) Reference: Rasmussen NUR2474 Module 1 (Pharmacokinetics); NCLEX Pharmacological
Therapies: Expected Actions/Outcomes.
Q2: A patient receiving IV morphine 4 mg q4h PRN for postoperative pain reports increased sedation
and respiratory rate of 10 breaths/min. The nurse understands that these findings represent which
pharmacodynamic concept?
A. Drug tolerance requiring increased dosing
B. Anaphylactic reaction to the opioid
C. Agonist effect at mu-opioid receptors exceeding therapeutic threshold [CORRECT]
D. Antagonist effect causing withdrawal symptoms
Correct Answer: C
Rationale:
● (a) Pharmacological principle: Morphine is a pure mu-opioid receptor agonist. At therapeutic
doses, it produces analgesia; however, excessive agonist activity causes dose-dependent
, adverse effects including respiratory depression (mediated by mu-2 receptors in the
brainstem respiratory centers) and sedation.
● (b) Clinical reasoning pathway: Assessment (RR 10, increased sedation = respiratory
depression) → Intervention (hold next dose, prepare naloxone, notify provider, monitor
oxygenation) → Evaluation (improved respiratory status after intervention).
● (c) Distractor analysis: A is incorrect because tolerance would require higher doses for effect,
not toxicity at current dose. B is incorrect because anaphylaxis presents with hypotension,
bronchospasm, and urticaria, not respiratory depression. D is incorrect because antagonists
block receptors and would cause withdrawal, not sedation.
● (d) Reference: Rasmussen NUR2474 Module 2 (Pharmacodynamics); NCLEX Reduction of
Risk Potential: System Specific Assessments.
Q3: A nurse is teaching a patient about warfarin therapy. Which statement by the patient
demonstrates understanding of the drug's mechanism of action?
A. "It dissolves blood clots that have already formed in my veins."
B. "It prevents my liver from making clotting factors that depend on vitamin K." [CORRECT]
C. "It makes my platelets less sticky so they don't clump together."
D. "It increases the breakdown of fibrin in my bloodstream."
Correct Answer: B
Rationale:
● (a) Pharmacological principle: Warfarin is a vitamin K antagonist that inhibits vitamin K
epoxide reductase (VKORC1), preventing the gamma-carboxylation of clotting factors II, VII,
IX, and X in the liver. This creates functionally inactive clotting factors, reducing coagulation
capacity.
● (b) Clinical reasoning pathway: Patient teaching (mechanism explanation) → Patient
response (accurate restatement) → Evaluation (understanding confirmed, adherence
promoted).
, ● (c) Distractor analysis: A describes thrombolytics (alteplase). C describes antiplatelet agents
(aspirin, clopidogrel). D describes fibrinolytic activity (not warfarin's mechanism).
● (d) Reference: Rasmussen NUR2474 Module 4 (Anticoagulants); NCLEX Pharmacological
Therapies: Medication Administration.
Q4: A patient with a history of liver cirrhosis is prescribed lorazepam 2 mg PO at bedtime for anxiety.
The nurse should anticipate which pharmacokinetic alteration?
A. Increased first-pass metabolism leading to lower bioavailability
B. Decreased metabolism leading to drug accumulation and prolonged effect [CORRECT]
C. Increased renal excretion of the active metabolite
D. Enhanced absorption due to portal hypertension
Correct Answer: B
Rationale:
● (a) Pharmacological principle: Lorazepam undergoes hepatic metabolism via glucuronidation
(Phase II). Cirrhosis reduces functional hepatocytes and hepatic blood flow, impairing drug
metabolism. This leads to prolonged elimination half-life, increased drug accumulation with
repeated dosing, and enhanced CNS depression.
● (b) Clinical reasoning pathway: Assessment (liver dysfunction + benzodiazepine order) →
Intervention (dose reduction, extended interval, or alternative drug; monitor for oversedation)
→ Evaluation (therapeutic effect without excessive sedation).
● (c) Distractor analysis: A is incorrect because first-pass metabolism is decreased, not
increased, in liver disease. C is incorrect because lorazepam's metabolites are inactive and
renal excretion is not clinically significant. D is incorrect because portal hypertension does not
enhance drug absorption.
● (d) Reference: Rasmussen NUR2474 Module 1 (Hepatic metabolism); NCLEX
Pharmacological Therapies: Adverse Effects/Contraindications/Side Effects.
